Studsvik’s Year-end Report 2025

Studsvik reported full-year 2025 net sales of SEK 883.3m (2024: SEK 893.1m) while delivering a material operational turnaround: operating profit SEK 68.6m (26.8) and operating margin 7.8% (3.0%), profit after tax SEK 37.3m (9.6) and free cash flow SEK 98.3m (–78.1). Net debt fell to SEK 65.1m from SEK 132.2m and EPS after tax rose to SEK 4.54 (1.17). The company secured new technology and service contracts (SMR CMS5 selection in Romania, inDRUM licensing and long-term agreements with KEPCO Nuclear Fuel and SCK CEN), and the board proposes no dividend to prioritize a pro-growth capital allocation and has authorization to issue up to 10% new shares.

Analysis

Market structure: Studsvik (Nasdaq Stockholm, small-cap nuclear services) and specialist SMR/fuel-test suppliers are clear beneficiaries — contracts with RoPower and KNF signal growing commercial demand for SMR licensing and fuel-flexibility testing, supporting a potential 5–8% annual service-market CAGR in the next 3–5 years. Pricing power should rise for niche services (software, irradiated fuel testing, inDRUM tech) because skilled-capacity is constrained; expect modest margin expansion of 200–400 bps if order backlog converts. Cross-asset: improved free cash flow (SEK98m) and lower net debt (SEK65m) should compress credit spreads for the company and similar small-cap service providers; modest SEK appreciation risk exists if export revenue grows.

Risk assessment: Tail risks include regulatory delays in Romania/Korea, a major licensing failure, or a 10%+ equity issuance (board authorized up to 10%) that would dilute EPS and cap gains; probability medium but impact high. Time horizons: immediate (days) volatility around AGM and quarterly call, short-term (weeks/months) dependent on new contract announcements, long-term (quarters/years) driven by SMR deployment timelines and sustained FCF. Hidden dependencies: concentration risk with a few strategic partners (KNF, SCK CEN, Korean licensee) and execution risk scaling lab capacity; catalysts include AGM decisions (share issuance), new contract awards in next 90 days, and quarterly FCF prints.

Trade implications: Direct: consider establishing a 2–3% long position in Studsvik (Nasdaq Stockholm) over the next 2–6 weeks, target +30–40% in 12 months, stop-loss -20% if margins fall below 6% or net debt rises >SEK90m. Sector: add 1–2% exposure to uranium/supply-chain via URA (Global X Uranium ETF) or URNM to capture broader SMR/utility re-rate; use 3–6 month call spreads on URA to limit premium. Pair trade: long Studsvik vs short a small-cap Swedish industrial basket (size-weighted) to isolate nuclear-service re-rating, rebalance monthly.

Contrarian angles: Consensus underestimates dilution and governance risk — the board’s 10% issuance authorization could be used to fund acquisitions or capex, pressuring near-term EPS; require a hard trigger (no issuance within 6 months) to hold beyond 15% paper gains. Historical parallels: niche engineering firms re-rated after multi-year contract flows, but many failed to scale operationally — verify capacity expansion plans and hiring timelines; unintended consequence: reinvestment focus removes dividends and can cap multiple expansion in the next 12–18 months.

Key Decisions for Investors

• Establish a 2–3% long position in Studsvik (Nasdaq Stockholm, small-cap nuclear services) within 2–6 weeks; target +30–40% over 12 months, set stop-loss at -20% or if reported operating margin falls below 6% or net debt exceeds SEK90m.
• Allocate 1–2% to uranium/supply-chain ETFs (URA or URNM) via 3–6 month call spreads (buy ITM/near-ATM, sell higher strike) to leverage sector momentum while capping premium; close if URA moves down 15% from entry.
• Implement a pair trade: long Studsvik (2%) vs short a small-cap Swedish industrial basket equal-weighted (2%) to isolate nuclear-service upside; rebalance monthly and unwind if Studsvik underperforms its cohort by >10% in 60 days.
• Monitor three binary catalysts in next 90 days and act: (1) AGM/share-issuance decision — if board announces equity raise >5% delay add-ons and reduce position by 50%; (2) new contract awards — add 50% to position on a multi-year, revenue-backed contract >SEK100m; (3) quarterly FCF — tighten stops if FCF turns negative or guidance is withdrawn.